SEC Form 4 · accession 0001628280-26-056752
Amneal Pharmaceuticals, Inc. · AMRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
J Kevin Buchi
Director
Period of report
Aug 11, 2026
Accepted (ET)
Aug 13, 2026 · 4:21 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001723128
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common StockF1 | Aug 11, 2026 | M | 168,573 | $17.18 | D | 93,499 | I | By Trust |
| Class A Common Stock | holding | — | — | — | 75,077 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.07 to $17.31 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.